One-year exenatide treatment improves beta cell response in metformin treated patients with type 2 diabetes which is sustained after 5 weeks discontinuation of treatment

被引：0
|
作者：
Bunck, M. C. [1 ]
Mari, A. [2 ]
Corner, A. [3 ]
Eliasson, B. [4 ]
Shaginian, R. M. [5 ]
Wu, Y. [6 ]
Yan, P. [6 ]
Heine, R. J. [1 ,7 ]
Smith, U. [4 ]
Taskinen, M. -R. [3 ]
Yki-Jarvinen, H. [3 ]
Diamant, M. [1 ]
机构：
[1] Vrije Univ Amsterdam, Med Ctr, Dept Endocrinol, Ctr Diabet, Amsterdam, Netherlands
[2] Inst Biomed Engn, Padua, Italy
[3] Univ Helsinki, Cent Hosp, Dept Med, FIN-00014 Helsinki, Finland
[4] Sahlgrens Univ Hosp, Lundberg Lab Diabet Res, S-41345 Gothenburg, Sweden
[5] Eli Lilly & Co, Houten, Netherlands
[6] Amylin Pharmaceut Inc, San Diego, CA USA
[7] Eli Lilly & Co, Indianapolis, IN 46285 USA
来源：
DIABETOLOGIA | 2009年 / 52卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1
引用
收藏
页码：S7 / S7
页数：1
相关论文
共 50 条
  • [41] Improvements in cardiovascular risk factors accompanied sustained effects on glycemia and weight reduction in patients with type 2 diabetes treated with exenatide for 82 weeks
    Kendall, D
    Kim, D
    Poon, T
    Hang, J
    Schnabel, C
    Fineman, M
    Trautmann, M
    Maggs, D
    DIABETOLOGIA, 2005, 48 : A389 - A389
  • [42] Mathematical modeling shows exenatide improved postprandial β-cell function in patients with type 2 diabetes treated with merformin or metformin and sulfonylurea
    Mari, A
    Halseth, A
    Nanayakkara, N
    Nielsen, L
    Defronzo, R
    Ferrannini, E
    DIABETES, 2005, 54 : A119 - A119
  • [43] Beta-Cell Function and Glycemic Control Following One-Year Vildagliptin Treatment, and after 12-Week Washout, in Drug-Naive Patients with Type 2 Diabetes and Mild Hyperglycemia
    Bunck, Mathijs C.
    Poelma, Marieke
    Goede, Diane L.
    Van Golen, Larissa W.
    Van Genugten, Renate E.
    Eekhoff, E. Marelise
    Schweizer, Anja
    Heine, Robert J.
    Foley, James E.
    Nijpels, Giel
    Diamant, Michaela
    DIABETES, 2010, 59 : A17 - A17
  • [44] PEGylated exenatide injection (PB-119) improves beta-cell function and insulin resistance in treatment-naive type 2 diabetes mellitus patients
    Liu, Xu
    Song, Ling
    Zhang, Yuanhui
    Li, Haiyan
    Cui, Cheng
    Liu, Dongyang
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [45] Treatment escalation options for patients with type 2 diabetes after failure of exenatide twice daily or glimepiride added to metformin: results from the prospective European Exenatide (EUREXA) study
    Schernthaner, G.
    Rosas-Guzman, J.
    Dotta, F.
    Guerci, B.
    Simo, R.
    Festa, A.
    Kiljanski, J.
    Zhou, M.
    Gallwitz, B.
    DIABETES OBESITY & METABOLISM, 2015, 17 (07): : 689 - 698
  • [46] Effect on beta cell function in newly diagnosed type 2 diabetes patients after treatment with vildagliptin and metformin: results from the VERIFY study
    Paldanius, P. M.
    Del Prato, S.
    Stumvoll, M.
    Matthews, D. R.
    DIABETOLOGIA, 2020, 63 (SUPPL 1) : S293 - S293
  • [47] Improvement in Postprandial Glucose after a 2-Year Treatment with Alogliptin in Patients with Type 2 Diabetes Inadequately Controlled with Metformin
    Liu, Jie
    Oh, Richard
    Wilson, Craig
    Camisasca, Riccardo
    DIABETES, 2014, 63 : A614 - A614
  • [48] One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes
    Hanefeld, M
    Brunetti, P
    Schernthaner, GH
    Matthews, DR
    Charbonnel, BH
    DIABETES CARE, 2004, 27 (01) : 141 - 147
  • [49] Beta cell function and response to treatment in Nigerians with Type 2 diabetes mellitus
    Oli, JM
    Adeyemo, AA
    Okafor, GO
    Ofoegbu, EN
    Onyenekwe, B
    Chukwuka, CJ
    Chen, G
    Chen, Y
    Doumatey, AP
    Aje, TO
    Rotimi, CN
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2005, 69 (02) : 196 - 204
  • [50] One-Year Treatment with Low Dose VI-0521 in Type 2 Diabetes Demonstrates Sustained Weight Loss and Continuous Glycemic Benefit
    Garvey, W. Timothy
    Troupin, Barbara
    Tam, Peter
    Najarian, Thomas
    Peterson, Craig
    Day, W. Wesley
    OBESITY, 2009, 17 : S52 - S52
12345